Possible association between the lrrk2 gene and anxiety behavior: a systematic literature review

References

• Alcalay, R. N., Mirelman, A., Saunders-Pullman, R., Tang, M. X., Mejia Santana, H., Raymond, D., Roos, E., Orbe-Reilly, M., Gurevich, T., Bar Shira, A., Gana Weisz, M., Yasinovsky, K., Zalis, M., Thaler, A., Deik, A., Barrett, M. J., Cabassa, J., Groves, M., Hunt, A. L.,… Marder, K. S. (2013). Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Movement Disorders: Official Journal of the Movement Disorder Society, 28(14), 1966–1971. doi:10.1002/mds.25647
   PubMed Web of Science ®Google Scholar
• Annunziata, M. A., Muzzatti, B., Bidoli, E., Flaiban, C., Bomben, F., Piccinin, M., Gipponi, K. M., Mariutti, G., Busato, S., & Mella, S. (2020). Hospital Anxiety and Depression Scale (HADS) accuracy in cancer patients. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 28(8), 3921–3926. doi:10.1007/s00520-019-05244-8
   PubMed Web of Science ®Google Scholar
• Atashrazm, F., & Dzamko, N. (2016). LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: Current perspectives. Clinical Pharmacology: Advances and Applications, 8, 177–189. doi:10.2147/CPAA.S102191
   PubMedGoogle Scholar
• Baig, F., Lawton, M., Rolinski, M., Ruffmann, C., Nithi, K., Evetts, S. G., Fernandes, H. R., Ben-Shlomo, Y., & Hu, M. T. (2015). Delineating nonmotor symptoms in early Parkinson’s disease and first-degree relatives. Movement Disorders: Official Journal of the Movement Disorder Society, 30(13), 1759–1766. doi:10.1002/mds.26281
   PubMed Web of Science ®Google Scholar
• Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues in Clinical Neuroscience, 19(2), 93–107. https://www.ncbi.nlm.nih.gov/pubmed/28867934
   PubMed Web of Science ®Google Scholar
• Bartlett, A. A., Singh, R., & Hunter, R. G. (2017). Anxiety and epigenetics. Advances in Experimental Medicine and Biology, 978, 145–166. doi:10.1007/978-3-319-53889-1_8.
   PubMed Web of Science ®Google Scholar
• Bartoli, F., Carretta, D., & Carrà, G. (2021). Comorbid anxiety and alcohol or substance use disorders: An overview. Textbook of addiction treatment (pp. 1315–1325). doi:Springer Milan
   Google Scholar
• Bichler, Z., Lim, H. C., Zeng, L., & Tan, E. K. (2013). Non-motor and motor features in LRRK2 transgenic mice. PLoS One, 8(7), e70249. doi:10.1371/journal.pone.0070249
   PubMed Web of Science ®Google Scholar
• Bolz, S. N., Salentin, S., Jennings, G., Haupt, V. J., Sterneckert, J., & Schroeder, M. (2021). Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor. Computational and Structural Biotechnology Journal, 19, 3674–3681. doi:10.1016/j.csbj.2021.06.013
   PubMed Web of Science ®Google Scholar
• Bonet-Ponce, L., & Cookson, M. R. (2021). LRRK2 recruitment, activity, and function in organelles. The FEBS Journal. doi:10.1111/febs.16099
   PubMed Web of Science ®Google Scholar
• Bourin, M., & Hascoët, M. (2003). The mouse light/dark box test. European Journal of Pharmacology, 463(1–3), 55–65. doi:10.1016/S0014-2999(03)01274-3
   PubMed Web of Science ®Google Scholar
• Bower, J. H., Grossardt, B. R., Maraganore, D. M., Ahlskog, J. E., Colligan, R. C., Geda, Y. E., Therneau, T. M., & Rocca, W. A. (2010). Anxious personality predicts an increased risk of Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society, 25(13), 2105–2113. doi:10.1002/mds.23230
   PubMed Web of Science ®Google Scholar
• Bregman, N., Thaler, A., Mirelman, A., Helmich, R. C., Gurevich, T., Orr-Urtreger, A., Marder, K., Bressman, S., Bloem, B. R., & Giladi, N. and LRRK2 Ashkenazi Jewish consortium. (2017). A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. Brain Structure & Function, 222(3), 1207–1218. doi:10.1007/s00429-016-1271-4
   PubMed Web of Science ®Google Scholar
• Bright, J. M., Carlisle, H. J., Toda, A. M. A., Murphy, M., Molitor, T. P., Wren, P., Andruska, K. M., Liu, E., & Barlow, C. (2021). Differential Inhibition of LRRK2 in Parkinson’s disease patient blood by a G2019S selective LRRK2 inhibitor. Movement Disorders: Official Journal of the Movement Disorder Society, 36(6), 1362–1371. doi:10.1002/mds.28490
   PubMed Web of Science ®Google Scholar
• Burroughs, S., & French, D. (2007). Depression and anxiety: Role of mitochondria. Current Anaesthesia & Critical Care, 18(1), 4–41. doi:10.1016/j.cacc.2007.01.007
   Google Scholar
• Byrne, G., Rosenfeld, G., Leung, Y., Qian, H., Raudzus, J., Nunez, C., & Bressler, B. (2017). Prevalence of anxiety and depression in patients with inflammatory bowel disease. Canadian Journal of Gastroenterology & Hepatology, 2017, 6496727. doi:10.1155/2017/6496727
   PubMed Web of Science ®Google Scholar
• Carola, V., D'Olimpio, F., Brunamonti, E., Mangia, F., & Renzi, P. (2002). Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice. Behavioural Brain Research, 134(1–2), 49–57. doi:10.1016/S0166-4328(01)00452-1
   PubMed Web of Science ®Google Scholar
• Carrozzino, D., Morberg, B. M., Siri, C., Pezzoli, G., & Bech, P. (2018). Evaluating psychiatric symptoms in Parkinson’s Disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R). Progress in Neuro-Psychopharmacology & Biological Psychiatry, 81, 131–137. doi:10.1016/j.pnpbp.2017.10.024
   PubMed Web of Science ®Google Scholar
• Chaudhuri, K. R., Odin, P., Antonini, A., & Martinez-Martin, P. (2011). Parkinson’s disease: The non-motor issues. Parkinsonism & Related Disorders, 17(10), 717–723. doi:10.1016/j.parkreldis.2011.02.018
   PubMed Web of Science ®Google Scholar
• Choi, K., Chun, J., Han, K., Park, S., Soh, H., Kim, J., Lee, J., Lee, H. J., Im, J. P., & Kim, J. S. (2019). Risk of anxiety and depression in patients with inflammatory bowel disease: A nationwide, population-based study. Journal of Clinical Medicine, 8(5), 654. doi:10.3390/jcm8050654
   PubMed Web of Science ®Google Scholar
• Cirnaru, M. D., Marte, A., Belluzzi, E., Russo, I., Gabrielli, M., Longo, F., Arcuri, L., Murru, L., Bubacco, L., Matteoli, M., Fedele, E., Sala, C., Passafaro, M., Morari, M., Greggio, E., Onofri, F., & Piccoli, G. (2014). LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience, 7, 49. doi:10.3389/fnmol.2014.00049.
   PubMed Web of Science ®Google Scholar
• Crum, R. M., Mojtabai, R., Lazareck, S., Bolton, J. M., Robinson, J., Sareen, J., Green, K. M., Stuart, E. A., Flair, L. L., Alvanzo, A. A., & Storr, C. L. (2013). A prospective assessment of reports of drinking to self-medicate mood symptoms with the incidence and persistence of alcohol dependence. JAMA Psychiatry, 70(7), 718–726. doi:10.1001/jamapsychiatry.2013.1098
   PubMed Web of Science ®Google Scholar
• da Silva E Silva, D. A., Frozino Ribeiro, A., Damasceno, S., Rocha, C. S., Berenguer de Matos, A. H., Boerngen-Lacerda, R., Correia, D., & Brunialti Godard, A. L. (2016). Inflexible ethanol intake: A putative link with the Lrrk2 pathway. Behavioural Brain Research, 313, 30–37. doi:10.1016/j.bbr.2016.07.001
   PubMed Web of Science ®Google Scholar
• Daviu, N., Bruchas, M. R., Moghaddam, B., Sandi, C., & Beyeler, A. (2019). Neurobiological links between stress and anxiety. Neurobiology of Stress, 11, 100191. doi:10.1016/j.ynstr.2019.100191
   PubMed Web of Science ®Google Scholar
• Dawson, G. R., & Tricklebank, M. D. (1995). Use of the elevated plus maze in the search for novel anxiolytic agents. Trends in Pharmacological Sciences, 16(2), 33–36. doi:10.1016/S0165-6147(00)88973-7
   PubMed Web of Science ®Google Scholar
• Dzamko, N. L. (2017). LRRK2 and the immune system. Advances in Neurobiology, 14, 123–143. doi:10.1007/978-3-319-49969-7_7
   PubMedGoogle Scholar
• Dzamko, N., & Halliday, G. M. (2012). An emerging role for LRRK2 in the immune system. Biochemical Society Transactions, 40(5), 1134–1139. doi:10.1042/BST20120119
   PubMed Web of Science ®Google Scholar
• Eriksen, M. B., and T. F. Frandsen. 2018. “The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review.” J Med Libr Assoc 106(4): 420–431. https://doi.org/10.5195/jmla.2018.345.
   Google Scholar
• Estanga, A., Rodriguez-Oroz, M. C., Ruiz-Martinez, J., Barandiaran, M., Gorostidi, A., Bergareche, A., Mondragon, E., Lopez de Munain, A., & Marti-Masso, J. F. (2014). Cognitive dysfunction in Parkinson’s disease related to the R1441G mutation in LRRK2. Parkinsonism & Related Disorders, 20(10), 1097–1100. doi:10.1016/j.parkreldis.2014.07.005
   PubMed Web of Science ®Google Scholar
• Esteves, A. R., Swerdlow, R. H., & Cardoso, S. M. (2014). LRRK2, a puzzling protein: Insights into Parkinson’s disease pathogenesis. Experimental Neurology, 261, 206–216. doi:10.1016/j.expneurol.2014.05.025
   PubMed Web of Science ®Google Scholar
• Filiou, M. D., & Sandi, C. (2019). Anxiety and brain mitochondria: A bidirectional crosstalk. Trends in Neurosciences, 42(9), 573–588. doi:10.1016/j.tins.2019.07.002
   PubMed Web of Science ®Google Scholar
• Giesert, F., Glasl, L., Zimprich, A., Ernst, L., Piccoli, G., Stautner, C., Zerle, J., Hölter, S. M., Vogt Weisenhorn, D. M., & Wurst, W. (2017). The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson’s disease in the mouse. Neurobiology of Disease, 105, 179–193. doi:10.1016/j.nbd.2017.05.013
   PubMed Web of Science ®Google Scholar
• Gilsbach, B. K., & Kortholt, A. (2014). Structural biology of the LRRK2 GTPase and kinase domains: Implications for regulation. Frontiers in Molecular Neuroscience, 7, 32. doi:10.3389/fnmol.2014.00032
   PubMed Web of Science ®Google Scholar
• Gunzler, S. A., Riley, D. E., Chen, S. G., Tatsuoka, C. M., Johnson, W. M., Mieyal, J. J., Walter, E. M., Whitney, C. M., Feng, I. J., Owusu-Dapaah, H., Mittal, S. O., & Wilson-Delfosse, A. L. (2018). Motor and non-motor features of Parkinson’s disease in LRRK2 G2019S carriers versus matched controls. Journal of the Neurological Sciences, 388, 203–207. doi:10.1016/j.jns.2018.03.025
   PubMed Web of Science ®Google Scholar
• Hallit, S., Haddad, C., Hallit, R., Akel, M., Obeid, S., Haddad, G., Soufia, M., Khansa, W., Khoury, R., Kheir, N., Elias Hallit, C. A., & Salameh, P. (2020). Validation of the Hamilton anxiety rating scale and state trait anxiety inventory A and B in Arabic among the Lebanese population. Clinical Epidemiology and Global Health, 8(4), 104–1109. doi:10.1016/j.cegh.2020.03.028
   Web of Science ®Google Scholar
• Herrero, M. J., Blanch, J., Peri, J. M., De Pablo, J., Pintor, L., & Bulbena, A. (2003). A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. General Hospital Psychiatry, 25(4), 277–283. doi:10.1016/S0163-8343(03)00043-4
   PubMed Web of Science ®Google Scholar
• Herrmann, C. (1997). International experiences with the Hospital Anxiety and Depression Scale–a review of validation data and clinical results. Journal of Psychosomatic Research, 42(1), 17–41. doi:10.1016/S0022-3999(96)00216-4
   PubMed Web of Science ®Google Scholar
• Hettema, J. M., Neale, M. C., & Kendler, K. S. (2001). A review and meta-analysis of the genetic epidemiology of anxiety disorders. The American Journal of Psychiatry, 158(10), 1568–1578. doi:10.1176/appi.ajp.158.10.1568
   PubMed Web of Science ®Google Scholar
• Hinkle, K. M., Yue, M., Behrouz, B., Dächsel, J. C., Lincoln, S. J., Bowles, E. E., Beevers, J. E., Dugger, B., Winner, B., Prots, I., Kent, C. B., Nishioka, K., Lin, W. L., Dickson, D. W., Janus, C. J., Farrer, M. J., & Melrose, H. L. (2012). LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Molecular Neurodegeneration, 7, 25. doi:10.1186/1750-1326-7-25.
   PubMed Web of Science ®Google Scholar
• Ho, P. W., Chang, E. E., Leung, C. T., Liu, H., Malki, Y., Pang, S. Y., Choi, Z. Y., Liang, Y., Lai, W. S., Ruan, Y., Leung, K. M., Yung, S., Mak, J. C., Kung, M. H., Ramsden, D. B., & Ho, S. L. (2022). Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects. NPJ Parkinson’s Disease, 8(1), 115. doi:10.1038/s41531-022-00386-9.
   PubMed Web of Science ®Google Scholar
• Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014). SYRCLE's risk of bias tool for animal studies. BMC Medical Research Methodology, 14, 43. doi:10.1186/1471-2288-14-43
   PubMed Web of Science ®Google Scholar
• Howlett, E. H., Jensen, N., Belmonte, F., Zafar, F., Hu, X., Kluss, J., Schüle, B., Kaufman, B. A., Greenamyre, J. T., & Sanders, L. H. (2017). LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease. Human Molecular Genetics, 26(22), 4340–4351. doi:10.1093/hmg/ddx320
   PubMed Web of Science ®Google Scholar
• Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., & Alessi, D. R. (2007). LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson’s disease mutants affect kinase activity. The Biochemical Journal, 405(2), 307–317. doi:10.1042/BJ20070209
   PubMed Web of Science ®Google Scholar
• Jennings, D., Huntwork-Rodriguez, S., Henry, A. G., Sasaki, J. C., Meisner, R., Diaz, D., Solanoy, H., Wang, X., Negrou, E., Bondar, V. V., Ghosh, R., Maloney, M. T., Propson, N. E., Zhu, Y., Maciuca, R. D., Harris, L., Kay, A., LeWitt, P., King, T. A.,… Troyer, M. D. (2022). Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease. Science Translational Medicine, 14(648), eabj2658. doi:10.1126/scitranslmed.abj2658.
   PubMed Web of Science ®Google Scholar
• Khedr, E. M., El Fetoh, N. A., Khalifa, H., Ahmed, M. A., & El Beh, K. M. (2013). Prevalence of non motor features in a cohort of Parkinson’s disease patients. Clinical Neurology and Neurosurgery, 115(6), 673–677. doi:10.1016/j.clineuro.2012.07.032
   PubMed Web of Science ®Google Scholar
• Khouzam, H. R. (2017). A review of trazodone use in psychiatric and medical conditions. Postgraduate Medicine, 129(1), 140–148. doi:10.1080/00325481.2017.1249265
   PubMed Web of Science ®Google Scholar
• Kim, Y. K., & Jeon, S. W. (2018). Neuroinflammation and the immune-kynurenine pathway in anxiety disorders. Current Neuropharmacology, 16(5), 574–582. doi:10.2174/1570159X15666170913110426
   PubMed Web of Science ®Google Scholar
• Kim, K. S., Marcogliese, P. C., Yang, J., Callaghan, S. M., Resende, V., Abdel-Messih, E., Marras, C., Visanji, N. P., Huang, J., Schlossmacher, M. G., Trinkle-Mulcahy, L., Slack, R. S., Lang, A. E., & Park, D. S. and Canadian Lrrk2 in Inflammation Team (CLINT). (2018). Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson’s disease. Proceedings of the National Academy of Sciences of the United States of America, 115(22), E5164–E5173. doi:10.1073/pnas.1718946115.
   PubMed Web of Science ®Google Scholar
• Kvaal, K., Ulstein, I., Nordhus, I. H., & Engedal, K. (2005). The Spielberger State-Trait Anxiety Inventory (STAI): the state scale in detecting mental disorders in geriatric patients. International Journal of Geriatric Psychiatry, 20(7), 629–634. doi:10.1002/gps.1330
   PubMed Web of Science ®Google Scholar
• Lai, H. M., Cleary, M., Sitharthan, T., & Hunt, G. E. (2015). Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis. Drug and Alcohol Dependence, 154, 1–13. doi:10.1016/j.drugalcdep.2015.05.031
   PubMed Web of Science ®Google Scholar
• Lewis, P. A. (2022). A step forward for LRRK2 inhibitors in Parkinson’s disease. Science Translational Medicine, 14(648), eabq7374. doi:10.1126/scitranslmed.abq7374.
   PubMed Web of Science ®Google Scholar
• Li, T., Yang, D., Zhong, S., Thomas, J. M., Xue, F., Liu, J., Kong, L., Voulalas, P., Hassan, H. E., Park, J. S., MacKerell, A. D., & Smith, W. W. (2014). Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson’s disease cell and mouse models. Human Molecular Genetics, 23(23), 6212–6222. doi:10.1093/hmg/ddu341
   PubMed Web of Science ®Google Scholar
• Lim, J., Bang, Y., Choi, J. H., Han, A., Kwon, M. S., Liu, K. H., & Choi, H. J. (2018). LRRK2 G2019S induces anxiety/depression-like behavior before the onset of motor dysfunction with 5-HT. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 38(7), 1611–1621. doi:10.1523/JNEUROSCI.4051-15.2017
   PubMed Web of Science ®Google Scholar
• Liu, W., Liu, X., Li, Y., Zhao, J., Liu, Z., Hu, Z., Wang, Y., Yao, Y., Miller, A. W., Su, B., Cookson, M. R., Li, X., & Kang, Z. (2017). LRRK2 promotes the activation of NLRC4 inflammasome during. The Journal of Experimental Medicine, 214(10), 3051–3066. doi:10.1084/jem.20170014
   PubMed Web of Science ®Google Scholar
• Marchand, A., Drouyer, M., Sarchione, A., Chartier-Harlin, M. C., & Taymans, J. M. (2020). LRRK2 phosphorylation, more than an epiphenomenon. Frontiers in Neuroscience, 14, 527. doi:10.3389/fnins.2020.00527
   PubMed Web of Science ®Google Scholar
• Margulis, A. V., Pladevall, M., Riera-Guardia, N., Varas-Lorenzo, C., Hazell, L., Berkman, N. D., Viswanathan, M., & Perez-Gutthann, S. (2014). Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle-Ottawa Scale and the RTI item bank. Clinical Epidemiology, 6, 359–368. doi:10.2147/CLEP.S66677
   PubMed Web of Science ®Google Scholar
• Marques, A. A., Bevilaqua, M. C., da Fonseca, A. M., Nardi, A. E., Thuret, S., & Dias, G. P. (2016). Gender differences in the neurobiology of anxiety: Focus on adult hippocampal neurogenesis. Neural Plasticity, 2016, 5026713. doi:10.1155/2016/5026713
   PubMed Web of Science ®Google Scholar
• Marras, C., Schüle, B., Schuele, B., Munhoz, R. P., Rogaeva, E., Langston, J. W., Kasten, M., Meaney, C., Klein, C., Wadia, P. M., Lim, S. Y., Chuang, R. S., Zadikof, C., Steeves, T., Prakash, K. M., de Bie, R. M., Adeli, G., Thomsen, T., Johansen, K. K.,… Lang, A. E. (2011). Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology, 77(4), 325–333. doi:10.1212/WNL.0b013e318227042d
   PubMed Web of Science ®Google Scholar
• Marteau, T. M., & Bekker, H. (1992). The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). The British Journal of Clinical Psychology, 31(3), 301–306. doi:10.1111/j.2044-8260.1992.tb00997.x
   PubMed Web of Science ®Google Scholar
• Martins de Carvalho, L., Fonseca, P. A. S., Paiva, I. M., Damasceno, S., Pedersen, A. S. B., da Silva E Silva, D., Wiers, C. E., Volkow, N. D., & Brunialti Godard, A. L. (2020). Identifying functionally relevant candidate genes for inflexible ethanol intake in mice and humans using a guilt-by-association approach. Brain and Behavior, 10(12), e01879. doi:10.1002/brb3.1879
   PubMed Web of Science ®Google Scholar
• Meier, S. M., & Deckert, J. (2019). Genetics of anxiety disorders. Current Psychiatry Reports, 21(3), 16. doi:10.1007/s11920-019-1002-7
   PubMed Web of Science ®Google Scholar
• Melrose, H. L., Dächsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., Kent, C. B., Korvatska, E., Taylor, J. P., Witten, L., Liang, Y. Q., Beevers, J. E., Boules, M., Dugger, B. N., Serna, V. A., Gaukhman, A., Yu, X., Castanedes-Casey, M., Braithwaite, A. T.,…. Farrer, M. J. (2010). Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiology of Disease, 40(3), 503–517. doi:10.1016/j.nbd.2010.07.010
   PubMed Web of Science ®Google Scholar
• Mestre, T. A., Pont-Sunyer, C., Kausar, F., Visanji, N. P., Ghate, T., Connolly, B. S., Gasca-Salas, C., Kern, D. S., Jain, J., Slow, E. J., Faust-Socher, A., Kasten, M., Wadia, P. M., Zadikoff, C., Kumar, P., de Bie, R. M., Thomsen, T., Lang, A. E., Schüle, B.,…. Marras, C. (2018). Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson’s disease nonparkinsonian relatives: A multicenter family study. Movement Disorders: Official Journal of the Movement Disorder Society, 33(6), 960–965. doi:10.1002/mds.27272
   PubMed Web of Science ®Google Scholar
• Mirelman, A., Alcalay, R. N., Saunders-Pullman, R., Yasinovsky, K., Thaler, A., Gurevich, T., Mejia-Santana, H., Raymond, D., Gana-Weisz, M., Bar-Shira, A., Ozelius, L., Clark, L., Orr-Urtreger, A., Bressman, S., Marder, K., & Giladi, N. and LRRK2 AJ Consortium. (2015). Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Movement Disorders: Official Journal of the Movement Disorder Society, 30(7), 981–986. doi:10.1002/mds.26213
   PubMed Web of Science ®Google Scholar
• Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012). LRRK2 inhibition attenuates microglial inflammatory responses. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32(5), 1602–1611. doi:10.1523/JNEUROSCI.5601-11.2012
   PubMed Web of Science ®Google Scholar
• Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. and PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. doi:10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. and PRISMA-P Group. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews, 4, 1. doi:10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Mufford, M. S., van der Meer, D., Andreassen, O. A., Ramesar, R., Stein, D. J., & Dalvie, S. (2021). A review of systems biology research of anxiety disorders. Revista Brasileira de Psiquiatria, 43(4), 414–423. doi:10.1590/1516-4446-2020-1090
   PubMed Web of Science ®Google Scholar
• Oliveira, P. R. S., de Matos, L. O., Araujo, N. M., Sant Anna, H. P., da Silva, D. A., Silva, E., Damasceno, A. K. A., Martins de Carvalho, L., Horta, B. L., Lima-Costa, M. F., Barreto, M. L., Wiers, C. E., Volkow, N. D., & Brunialti Godard, A. L. (2021). Gene variants associated with a higher risk for alcohol dependence in multiethnic populations. Frontiers in Psychiatry, 12, 665257. doi:10.3389/fpsyt.2021.665257
   PubMed Web of Science ®Google Scholar
• Olthuis, J. V., Watt, M. C., Bailey, K., Hayden, J. A., & Stewart, S. H. (2016). Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. The Cochrane Database of Systematic Reviews, 3(3), CD011565. doi:10.1002/14651858.CD011565.
   PubMed Web of Science ®Google Scholar
• Paiva, I. M., de Carvalho, L. M., Di Chiaccio, I. M., Lima Assis, I., Naranjo, E. S., Bernabé, M. G., Ferreira, F. N. A., Cayuela, M. L., Murgas, L. D. S., & Brunialti Godard, A. L. (2020). Inhibition of Lrrk2 reduces ethanol preference in a model of acute exposure in zebrafish. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 100, 109885. doi:10.1016/j.pnpbp.2020.109885
   PubMed Web of Science ®Google Scholar
• Patel, A., Patel, S., Mehta, M., Patel, Y., Langaliya, D., Bhalodiya, S., & Bambharoliya, T. (2022). Recent update on the development of leucine-rich repeat kinase 2 (LRRK2) inhibitors: A promising target for the treatment of Parkinson’s disease. Medicinal Chemistry, 18(7), 757–771. doi:10.2174/1573406418666220215122136
   PubMed Web of Science ®Google Scholar
• Pontone, G. M., Williams, J. R., Anderson, K. E., Chase, G., Goldstein, S. R., Grill, S., Hirsch, E. S., Lehmann, S., Little, J. T., Margolis, R. L., Palanci, J., Rabins, P. V., Weiss, H. D., & Marsh, L. (2013). Pharmacologic treatment of anxiety disorders in Parkinson disease. The American Journal of Geriatric Psychiatry, 21(6), 520–528. doi:10.1016/j.jagp.2012.10.023
   PubMed Web of Science ®Google Scholar
• Pont-Sunyer, C., Iranzo, A., Gaig, C., Fernández-Arcos, A., Vilas, D., Valldeoriola, F., Compta, Y., Fernández-Santiago, R., Fernández, M., Bayés, A., Calopa, M., Casquero, P., de Fàbregues, O., Jaumà, S., Puente, V., Salamero, M., José Martí, M., Santamaría, J., & Tolosa, E. (2015). Sleep disorders in parkinsonian and nonparkinsonian LRRK2 mutation carriers. PLoS One, 10(7), e0132368. doi:10.1371/journal.pone.0132368
   PubMed Web of Science ®Google Scholar
• Remes, O., Brayne, C., van der Linde, R., & Lafortune, L. (2016). A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain and Behavior, 6(7), e00497. doi:10.1002/brb3.497
   PubMed Web of Science ®Google Scholar
• Ren, C., Ding, Y., Wei, S., Guan, L., Zhang, C., Ji, Y., Wang, F., Yin, S., & Yin, P. (2019). G2019S Variation in LRRK2: An ideal model for the study of Parkinson’s disease? Frontiers in Human Neuroscience., 13, 306. doi:10.3389/fnhum.2019.00306.
   PubMed Web of Science ®Google Scholar
• Reynolds, G. O., Saint-Hilaire, M., Thomas, C. A., Barlow, D. H., & Cronin-Golomb, A. (2020). Cognitive-behavioral therapy for anxiety in Parkinson’s disease. Behavior Modification, 44(4), 552–579. doi:10.1177/0145445519838828
   PubMed Web of Science ®Google Scholar
• Robinson, O. J., Pike, A. C., Cornwell, B., & Grillon, C. (2019). The translational neural circuitry of anxiety. Journal of Neurology, Neurosurgery, and Psychiatry, 90(12), 1353–1360. doi:10.1136/jnnp-2019-321400
   PubMed Web of Science ®Google Scholar
• Russo, I., Bubacco, L., & Greggio, E. (2022). LRRK2 as a target for modulating immune system responses. Neurobiology of Disease, 169, 105724. doi:10.1016/j.nbd.2022.105724
   PubMed Web of Science ®Google Scholar
• Sakharkar, A. J., Kyzar, E. J., Gavin, D. P., Zhang, H., Chen, Y., Krishnan, H. R., Grayson, D. R., & Pandey, S. C. (2019). Altered amygdala DNA methylation mechanisms after adolescent alcohol exposure contribute to adult anxiety and alcohol drinking. Neuropharmacology, 157, 107679. doi:10.1016/j.neuropharm.2019.107679
   PubMed Web of Science ®Google Scholar
• Salari, M., Zali, A., Ashrafi, F., Etemadifar, M., Sharma, S., Hajizadeh, N., & Ashourizadeh, H. (2020). Incidence of anxiety in Parkinson’s disease during the coronavirus disease (COVID-19) pandemic. Movement Disorders: Official Journal of the Movement Disorder Society, 35(7), 1095–1096. doi:10.1002/mds.28116
   PubMed Web of Science ®Google Scholar
• Salim, S., Chugh, G., & Asghar, M. (2012). Inflammation in anxiety. Advances in Protein Chemistry and Structural Biology, 88, 1–25. doi:10.1016/B978-0-12-398314-5.00001-5.
   PubMed Web of Science ®Google Scholar
• Sanchez, T. A., Rizzo Duarte de Carvalho, J., Ramos, L. R., da Fonseca, L. M. B., Gomes, M. K., Jandre dos Reis, F. J., & Gasparetto, E. L. (2021). Brain emotional reactivity with anxiety symptoms in treated leprosy patients: An evaluation of a stigmatized condition. Stigma and Health, 6(3), . 54–362. doi: 10.1037/sah0000278
   Google Scholar
• Schapansky, J., Nardozzi, J. D., Felizia, F., & LaVoie, M. J. (2014). Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Human Molecular Genetics, 23(16), 4201–4214. doi:10.1093/hmg/ddu138
   PubMed Web of Science ®Google Scholar
• Schiele, M. A., & Domschke, K. (2018). Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders. Genes, Brain, and Behavior, 17(3), e12423. doi:10.1111/gbb.12423
   PubMed Web of Science ®Google Scholar
• Schinka, J. A., Busch, R. M., & Robichaux-Keene, N. (2004). A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Molecular Psychiatry, 9(2), 197–202. doi:10.1038/sj.mp.4001405
   PubMed Web of Science ®Google Scholar
• Schneider, R. B., Auinger, P., Tarolli, C. G., Iourinets, J., Gil-Díaz, M. C., & Richard, I. H. (2020). A trial of buspirone for anxiety in Parkinson’s disease: Safety and tolerability. Parkinsonism & Related Disorders, 81, 69–74. doi:10.1016/j.parkreldis.2020.10.020
   PubMed Web of Science ®Google Scholar
• Schrag, A., & Taddei, R. N. (2017). Depression and anxiety in Parkinson’s disease. International Review of Neurobiology, 133, 623–655. doi:10.1016/bs.irn.2017.05.024.
   PubMed Web of Science ®Google Scholar
• Seegobin, S. P., Heaton, G. R., Liang, D., Choi, I., Ramirez, M. B., Tang, B., & Yue, Z. (2020). Progress in LRRK2-associated Parkinson’s disease animal models. Frontiers in Neuroscience, 14, 674. doi:10.3389/fnins.2020.00674.
   PubMed Web of Science ®Google Scholar
• Selçuk, A. A. (2019). A guide for systematic reviews: PRISMA. Turkish Archives of Otorhinolaryngology, 57(1), 57–58. doi: 10.5152/tao.2019.4058.
   PubMed Web of Science ®Google Scholar
• Seritan, A. L., Rienas, C., Duong, T., Delucchi, K., & Ostrem, J. L. (2019). Ages at onset of anxiety and depressive disorders in Parkinson’s disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 31(4), 346–352. doi:10.1176/appi.neuropsych.18090201
   PubMed Web of Science ®Google Scholar
• Shanker, V., Groves, M., Heiman, G., Palmese, C., Saunders-Pullman, R., Ozelius, L., Raymond, D., & Bressman, S. (2011). Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society, 26(10), 1875–1880. doi:10.1002/mds.23746
   PubMed Web of Science ®Google Scholar
• Sharmin, S., Kypri, K., Khanam, M., Wadolowski, M., Bruno, R., & Mattick, R. P. (2017). Parental supply of alcohol in childhood and risky drinking in adolescence: Systematic review and meta-analysis. International Journal of Environmental Research and Public Health, 14(3), 287. doi:10.3390/ijerph14030287
   PubMed Web of Science ®Google Scholar
• Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., Solanoy, H. O., Drummond, J., Zhang, X., Ding, X., Cai, F., Song, Q., Li, X., Yue, Z., van der Brug, M. P., Burdick, D. J., Gunzner-Toste, J., Chen, H., Liu, X.,… Zhu, H. (2012). Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Science Translational Medicine, 4(164), 164–ra161. doi:10.1126/scitranslmed.3004485.
   Web of Science ®Google Scholar
• Shin, N., Jeong, H., Kwon, J., Heo, H. Y., Kwon, J. J., Yun, H. J., Kim, C. H., Han, B. S., Tong, Y., Shen, J., Hatano, T., Hattori, N., Kim, K. S., Chang, S., & Seol, W. (2008). LRRK2 regulates synaptic vesicle endocytosis. Experimental Cell Research, 314(10), 2055–2065. doi:10.1016/j.yexcr.2008.02.015
   PubMed Web of Science ®Google Scholar
• Shu, L., Zhang, Y., Sun, Q., Pan, H., & Tang, B. (2019). A comprehensive analysis of population differences in LRRK2 variant distribution in Parkinson’s disease. Frontiers in Aging Neuroscience, 11, 13. doi:10.3389/fnagi.2019.00013
   PubMed Web of Science ®Google Scholar
• Simuni, T., Uribe, L., Cho, H. R., Caspell-Garcia, C., Coffey, C. S., Siderowf, A., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., Singleton, A., Toga, A. W., Galasko, D., Foroud, T., Tosun, D., Poston, K., Weintraub, D., Mollenhauer, B., Tanner, C. M., Kieburtz, K.,… Investigators, PPMI. (2020). Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI): A cross-sectional study. Lancet Neurology, 19(1), 71–80. doi:10.1016/S1474-4422(19)30319-9
   PubMed Web of Science ®Google Scholar
• Singh, A., Zhi, L., & Zhang, H. (2019). LRRK2 and mitochondria: Recent advances and current views. Brain Research, 1702, 96–104. doi:10.1016/j.brainres.2018.06.010
   PubMed Web of Science ®Google Scholar
• Somar, P., Waltz, M. M., & van Brakel, W. H. (2020). The impact of leprosy on the mental wellbeing of leprosy-affected persons and their family members - a systematic review. Global Mental Health (Cambridge, England)), 7, e15. doi:10.1017/gmh.2020.3.
   PubMed Web of Science ®Google Scholar
• Spinhoven, P., Ormel, J., Sloekers, P. P., Kempen, G. I., Speckens, A. E., & Van Hemert, A. M. (1997). A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychological Medicine, 27(2), 363–370. doi:10.1017/s0033291796004382
   PubMed Web of Science ®Google Scholar
• Tan, E. K., Peng, R., Teo, Y. Y., Tan, L. C., Angeles, D., Ho, P., Chen, M. L., Lin, C. H., Mao, X. Y., Chang, X. L., Prakash, K. M., Liu, J. J., Au, W. L., Le, W. D., Jankovic, J., Burgunder, J. M., Zhao, Y., & Wu, R. M. (2010). Multiple LRRK2 variants modulate risk of Parkinson disease: A Chinese multicenter study. Human Mutation, 31(5), 561–568. doi:10.1002/humu.21225.
   PubMed Web of Science ®Google Scholar
• Thaler, A., Gonen, T., Mirelman, A., Helmich, R. C., Gurevich, T., Orr-Urtreger, A., Bloem, B. R., Giladi, N., & Hendler, T. and LRRK2 Ashkenazi Jewish Consortium. (2019). Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation. Brain Imaging and Behavior, 13(4), 1009–1020. doi:10.1007/s11682-018-9920-2
   PubMed Web of Science ®Google Scholar
• Trinh, J., Gustavsson, E. K., Vilariño-Güell, C., Bortnick, S., Latourelle, J., McKenzie, M. B., Tu, C. S., Nosova, E., Khinda, J., Milnerwood, A., Lesage, S., Brice, A., Tazir, M., Aasly, J. O., Parkkinen, L., Haytural, H., Foroud, T., Myers, R. H., Sassi, S. B.,.Farrer, M. J. (2016). DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser Parkinsonism: A genome-wide linkage and association study. The Lancet Neurology, 15(12), 1248–1256. doi:10.1016/S1474-4422(16)30203-4
   PubMed Web of Science ®Google Scholar
• Tyrer, P., & Baldwin, D. (2006). Generalised anxiety disorder. Lancet, 368(9553), 2156–2166. doi:10.1016/S0140-6736(06)69865-6
   PubMed Web of Science ®Google Scholar
• Vermilyea, S. C., & Emborg, M. E. (2018). In vitro modeling of leucine-rich repeat kinase 2 G2019S-mediated Parkinson’s disease pathology. Stem Cells and Development, 27(14), 960–967. doi:10.1089/scd.2017.0286
   PubMed Web of Science ®Google Scholar
• Vilas, D., Segura, B., Baggio, H. C., Pont-Sunyer, C., Compta, Y., Valldeoriola, F., José Martí, M., Quintana, M., Bayés, A., Hernández-Vara, J., Calopa, M., Aguilar, M., Junqué, C., & Tolosa, E. and the Barcelona LRRK2 Study Group. (2016). Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study. Movement Disorders: Official Journal of the Movement Disorder Society, 31(12), 1820–1828. doi:10.1002/mds.26799
   PubMed Web of Science ®Google Scholar
• Wallings, R., Manzoni, C., & Bandopadhyay, R. (2015). Cellular processes associated with LRRK2 function and dysfunction. The FEBS Journal, 282(15), 2806–2826. doi:10.1111/febs.13305
   PubMed Web of Science ®Google Scholar
• Wallings, R. L., & Tansey, M. G. (2019). LRRK2 regulation of immune-pathways and inflammatory disease. Biochemical Society Transactions, 47(6), 1581–1595. doi:10.1042/BST20180463
   PubMed Web of Science ®Google Scholar
• Walsh, K., & Bennett, G. (2001). Parkinson’s disease and anxiety. Postgraduate Medical Journal, 77(904), 89–93. doi:10.1136/pmj.77.904.89
   PubMed Web of Science ®Google Scholar
• Weindel, C. G., Bell, S. L., Vail, K. J., West, K. O., Patrick, K. L., & Watson, R. O. (2020). LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis. eLife, 9, e51071. doi:10.7554/eLife.51071
   PubMed Web of Science ®Google Scholar
• Wells, G. A., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (2014). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Applied Engineering in Agriculture, 18(6), 727–734. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• West, A. B. (2017). Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Experimental Neurology, 298(Pt B), 236–245. doi:10.1016/j.expneurol.2017.07.019
   PubMed Web of Science ®Google Scholar
• Xiao, Q., Yang, S., & Le, W. (2015). G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system. Journal of Neural Transmission, 122(12), 1645–1657. doi:10.1007/s00702-015-1438-9
   PubMed Web of Science ®Google Scholar
• Xiong, Y., Dawson, T. M., & Dawson, V. L. (2017). Models of LRRK2-associated Parkinson’s disease. Advances in Neurobiology, 14, 163–191. doi:10.1007/978-3-319-49969-7_9.
   PubMedGoogle Scholar
• Yamanishi, T., Tachibana, H., Oguru, M., Matsui, K., Toda, K., Okuda, B., & Oka, N. (2013). Anxiety and depression in patients with Parkinson’s disease. Internal Medicine (Tokyo, Japan), 52(5), 539–545. doi:10.2169/internalmedicine.52.8617
   PubMed Web of Science ®Google Scholar
• Zingano, B. L., Guarnieri, R., Diaz, A. P., Schwarzbold, M. L., Wolf, P., Lin, K., & Walz, R. (2019). Hospital anxiety and depression scale-anxiety subscale (HADS-A) and the state-trait anxiety inventory (STAI) accuracy for anxiety disorders detection in drug-resistant mesial temporal lobe epilepsy patients. Journal of Affective Disorders, 246, 452–457. doi:10.1016/j.jad.2018.12.072
   PubMed Web of Science ®Google Scholar